Skip to main content

Advertisement

SpringerLink
Log in

Management of Lower Urinary Tract Symptoms after Prostate Radiation

  • Lower Urinary Tract Symptoms and Voiding Dysfunction (J Sandhu, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To present urologists with guidance on how to approach and manage lower urinary tract symptoms (LUTS) in patients who have undergone radiation therapy (RT) for prostate cancer.

Recent Findings

There are few studies that specifically examine treatment approaches for LUTS in patients who have undergone prostate cancer RT.

Summary

LUTS after prostate RT are unique when compared to de novo LUTS. Understanding these distinctions is important for urologists’ practice as well as patients’ quality of life. Discussion of the risks and management of post-RT LUTS should be included in the shared decision-making process when counseling patients on various treatment options for prostate cancer. Further studies evaluating treatments for storage and voiding symptoms after RT are needed to help guide future care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.

    PubMed  Google Scholar 

  2. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.

    PubMed  PubMed Central  Google Scholar 

  3. Pollack A, Karrison TG, Balogh AG Jr, Low D, Bruner DW, Wefel JS, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys. 2018;102(5):1605.

    Google Scholar 

  4. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized Phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.

    PubMed  PubMed Central  Google Scholar 

  5. As NJV, Brand D, Tree A, Ostler PJ, Chu W, Loblaw A, et al. PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa). J Clin Oncol. 2019;37(7_suppl):1.

    Google Scholar 

  6. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys. 2007;67(1):39–47.

    PubMed  Google Scholar 

  7. NICE (National Institute for Health and Care Excellence U. Clinical Guideline: Lower urinary tract symptoms in men: management (CG97). 2010. UK: www.nice.org.uk/guidance/cg97.

  8. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.

    PubMed  Google Scholar 

  9. •• Sandhu JS, Breyer B, Comiter C, Eastham JA, Gomez C, Kirages DJ, et al. Incontinence after prostate treatment: AUA/SUFU Guideline. J Urol. 2019;202(2):369–78 Comprehensive review of recommendations on the management of incontinence after prostate treatment compiled by a national urologic society.

    PubMed  Google Scholar 

  10. Blaivas JG, Weiss JP, Jones M. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer. BJU Int. 2006;98(6):1233–7.

    PubMed  Google Scholar 

  11. Cancer Stat Facts: Prostate Cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 7/07/20.

  12. National Comprehensive Cancer Network. Prostate Cancer. In: NCCN Evidence BlocksTM. 2020.

  13. Chen J, Oromendia C, Halpern JA, Ballman KV. National trends in management of localized prostate cancer: a population based analysis 2004-2013. Prostate. 2018;78(7):512–20.

    PubMed  Google Scholar 

  14. Glaser J, Nouri S, Fernandez A, Sudore RL, Schillinger D, Klein-Fedyshin M, et al. Interventions to improve patient comprehension in informed consent for medical and surgical procedures: an updated systematic review. Med Decis Mak. 2020;40(2):119–43.

    Google Scholar 

  15. Dinh TT, Lee HJ Jr, Macomber MW, Apisarnthanarax S, Zeng J, Laramore GE, et al. Rectal hydrogel spacer improves late gastrointestinal toxicity compared to rectal balloon immobilization after proton beam radiation therapy for localized prostate cancer: a retrospective observational study. Int J Radiat Oncol Biol Phys. 2020;S0360-3016(20):30152–8.

    Google Scholar 

  16. Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a Phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–85.

    PubMed  Google Scholar 

  17. Rodda S, Morris WJ, Hamm J, Duncan G. ASCENDE-RT: An analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(3):581–9.

    PubMed  Google Scholar 

  18. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6. https://doi.org/10.1016/0360-3016(95)00060-C.

    Article  CAS  PubMed  Google Scholar 

  19. Yoshida K, Yamazaki H, Nakamara S, Masui K, Kotsuma T, Akiyama H, et al. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer. Anticancer Res. 2014;34(4):2015–8.

    PubMed  Google Scholar 

  20. • Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate ancer. N Engl J Med. 2016;375(15):1425–37 Provides an analysis of patient-reported outcomes and quality of life data spanning a wide array of health domains after prostate cancer treatment.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Nicholas S, Chen L, Choflet A, Fader A, Guss Z, Hazell S, et al. Pelvic radiation and normal tissue toxicity. Semin Radiat Oncol. 2017;27(4):358–69.

    PubMed  Google Scholar 

  22. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991;21(4):935–9.

    CAS  PubMed  Google Scholar 

  23. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11(1):6–19.

    PubMed  Google Scholar 

  24. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol. 2002;41(4):427–33.

    CAS  PubMed  Google Scholar 

  25. Prestidge BR, Winter K, Sanda MG, Amin M, Bice WS Jr, Michalski J, et al. Initial Report of NRG Oncology/RTOG 0232: a phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2016;96(2):S4.

    Google Scholar 

  26. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018;4(6):e180039.

    PubMed  PubMed Central  Google Scholar 

  27. Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018;102(2):296–303.

    PubMed  Google Scholar 

  28. Meier R, Cotrutz C, Loiselle C, Sima S, Vermeulen S. Long-term outcomes of stereotactic body radiation therapy for organ-confined prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84:S417.

    Google Scholar 

  29. Meier R. Dose-wscalated robotic SBRT for stage I-II prostate cancer. Front Oncol. 2015;5:48.

    PubMed  PubMed Central  Google Scholar 

  30. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yamada K, Okihara K, et al. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Radiother Oncol. 2019;132:162–70.

    PubMed  Google Scholar 

  31. Crook J, Marban M, Batchelar D. HDR prostate brachytherapy. Semin Radiat Oncol. 2020;30(1):49–60.

    PubMed  Google Scholar 

  32. Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J. Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. BJU Int. 2017;120(1):56–60.

    CAS  PubMed  Google Scholar 

  33. Gormley E, Lightner D, Burgio K, Chai T, Clemens J, Culkin D, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. Linthicum, MD: American Urological Association Education and Research, Inc.®.

  34. International Prostate Symptom Score (I-PSS). http://www.urospec.com/uro/Forms/ipss.pdf. Accessed 6/11/2020.

  35. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.

    CAS  PubMed  Google Scholar 

  36. Kurzawa Z, Sutherland JM, Crump T, Liu G. Measuring quality of life in patients with stress urinary incontinence: is the ICIQ-UI-SF adequate? Qual Life Res. 2018;27(8):2189–94.

    PubMed  Google Scholar 

  37. •• Hoffman D, Vijay V, Peng M, Sussman RD, Rosenblum N, Brucker BM, et al. Effect of radiation on male stress urinary incontinence and the role of urodynamic assessment. Urology. 2019;125:58–63 Questions the utility of information obtained from UDS when managing SUI in patients after RT.

    PubMed  Google Scholar 

  38. Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, et al. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: a secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016;34(10):430 e431–7.

    Google Scholar 

  39. Biers S, Sievert KD, Thiruchelvam N. Overactive bladder syndrome and lower urinary tract symptoms after prostate cancer treatment. Curr Opin Urol. 2017;27(3):307–13.

    PubMed  Google Scholar 

  40. Choo R, Do V, Herschorn S, DeBoer G, Danjoux C, Morton G, et al. Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;53(2):290–6.

    PubMed  Google Scholar 

  41. Bernard S, Ouellet MP, Moffet H, Roy JS, Dumoulin C. Effects of radiation therapy on the structure and function of the pelvic floor muscles of patients with cancer in the pelvic area: a systematic review. J Cancer Surviv. 2016;10(2):351–62.

    PubMed  Google Scholar 

  42. Dieperink KB, Johansen C, Hansen S, Wagner L, Andersen KK, Minet LR, et al. The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients. Br J Cancer. 2013;109(12):3005–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Lorenzi B, Brading AF, Martellucci J, Cetta F, Mortensen NJ. Short-term effects of neoadjuvant chemoradiotherapy on internal anal sphincter function: a human in vitro study. Dis Colon Rectum. 2012;55(4):465–72.

    PubMed  Google Scholar 

  44. Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology. 2001;219(3):817–21.

    CAS  PubMed  Google Scholar 

  45. Marigliano C, Donati OF, Vargas HA, Akin O, Goldman DA, Eastham JA, et al. MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer. Eur J Radiol. 2013;82(12):e775–81.

    PubMed  PubMed Central  Google Scholar 

  46. Faithfull S, Lemanska A, Aslet P, Bhatt N, Coe J, Drudge-Coates L, et al. Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. Int J Clin Pract. 2015;69(10):1184–208.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. • Oscarsson N, Muller B, Rosen A, Lodding P, Molne J, Giglio D, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol. 2019;20(11):1602–14 Highlights the benefit of a relatively low-risk therapy for LUTS after RT.

    PubMed  Google Scholar 

  48. Bittner N, Merrick GS, Brammer S, Niehaus A, Wallner KE, Butler WM, et al. Role of trospium chloride in brachytherapy-related detrusor overactivity. Urology. 2008;71(3):460–4.

    PubMed  Google Scholar 

  49. Jaszczynski J, Kojs Z, Stelmach A, Wohadlo L, Luczynska E, Heinze S, et al. Post-irradiation bladder syndrome after radiotherapy of malignant neoplasm of small pelvis organs: an observational, non-interventional clinical study assessing VESIcare(R)/Solifenacin treatment results. Med Sci Monit. 2016;22:2691–8.

    PubMed  PubMed Central  Google Scholar 

  50. Yan M, Xue P, Wang K, Gao G, Zhang W, Sun F. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone?: a prospective, randomized, controlled trial. Strahlenther Onkol. 2017;193(9):714–21.

    PubMed  Google Scholar 

  51. Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, et al. Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment. Eur Urol. 2019;76(6):767–79.

    CAS  PubMed  Google Scholar 

  52. Chuang YC, Kim DK, Chiang PH, Chancellor MB. Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. BJU Int. 2008;102(6):704–6.

    CAS  PubMed  Google Scholar 

  53. Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):567–70.

    CAS  PubMed  Google Scholar 

  54. Tsumura H, Satoh T, Ishiyama H, Tabata K, Kotani S, Minamida S, et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys. 2011;81(4):e385–92.

    CAS  PubMed  Google Scholar 

  55. Oyama N, Aoki Y, Ito H, Miwa Y, Akino H, Sato Y, et al. Alpha 1-adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by (125) I brachytherapy for prostate cancer. ISRN Urol. 2014;2014:140654.

    PubMed  PubMed Central  Google Scholar 

  56. Tanaka N, Torimoto K, Asakawa I, Miyake M, Anai S, Hirayama A, et al. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer-a randomized controlled trial of silodosin versus naftopidil. Radiat Oncol. 2014;9:302.

    PubMed  PubMed Central  Google Scholar 

  57. Shimizu N, Minami T, Sugimoto K, Saito Y, Yamamoto Y, Hayashi T, et al. Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. World J Urol. 2014;32(6):1423–32.

    CAS  PubMed  Google Scholar 

  58. Polland A, Vertosick EA, Sjoberg DD, Stearns GL, Leddy LS, Kollmeier MA, et al. Preoperative symptoms predict continence after post-radiation transurethral resection of prostate. Can J Urol. 2017;24(4):8903–9.

    PubMed  Google Scholar 

  59. Mock S, Leapman M, Stock RG, Hall SJ, Stone NN. Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters. J Urol. 2013;190(5):1805–10.

    PubMed  Google Scholar 

  60. Mabjeesh NJ, Chen J, Stenger A, Matzkin H. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology. 2007;70(3):548–53.

    PubMed  Google Scholar 

  61. Parsons JK, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical mnagement of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE. J Urol. 2018;200:612–19. https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline.

  62. Leapman MS, Stone NN, Mock S, Stock RG, Hall SJ. Urinary incontinence following prostate brachytherapy. Urology. 2016;95:151–7.

    PubMed  Google Scholar 

  63. Fuller TW, Ballon-Landa E, Gallo K, Smith TG 3rd, Ajay D, Westney OL, et al. Outcomes and risk factors of revision and replacement artificial urinary sphincter implantation in radiated and nonradiated cases. J Urol. 2020;204(1):110–4.

    PubMed  Google Scholar 

  64. • Jahromi MS, Engle K, Furlong D, Guevara Mendez A, Gomez CS. Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement. Neurourol Urodyn. 2020;39(5):1489–93 Compares outcomes of AUS in irradiated and nonirradiated patients. Highlights the increased rate of storage symptoms and need for treatment of storage-related LUTS post-RT.

    PubMed  Google Scholar 

  65. Chung ASJ, Suarez OA, McCammon KA. AdVance male sling. Transl Androl Urol. 2017;6(4):674–81.

    PubMed  PubMed Central  Google Scholar 

  66. Zuckerman JM, Tisdale B, McCammon K. AdVance male sling in irradiated patients with stress urinary incontinence. Can J Urol. 2011;18(6):6013–7.

    PubMed  Google Scholar 

  67. Larson T, Jhaveri H, Yeung LL. Adjustable continence therapy (ProACT) for the treatment of male stress urinary incontinence: a systematic review and meta-analysis. Neurourol Urodyn. 2019;38(8):2051–9.

    PubMed  Google Scholar 

  68. Sack BS, Langenstroer P, Guralnick ML, Jacobsohn KM, O'Connor RC. Cystectomy and urinary diversion for the management of a devastated lower urinary tract following prostatic cryotherapy and/or radiotherapy. WMJ. 2016;115(2):70–3.

    PubMed  Google Scholar 

  69. Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ, Tran NV, et al. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol. 2005;173(6):1953–7.

    PubMed  Google Scholar 

  70. Osterberg EC, Vanni AJ, Gaither TW, Awad MA, Broghammer JA, Pate SC, et al. Radiation-induced complex anterior urinary fistulation for prostate cancer: a retrospective multicenter study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS). World J Urol. 2017;35(7):1037–43.

    PubMed  Google Scholar 

  71. Awad MA, Gaither TW, Osterberg EC, Murphy GP, Baradaran N, Breyer BN. Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21(2):168–74.

    PubMed  Google Scholar 

  72. Keith CG, Davenport MT, Kavoussi M, Yi YA, Bergeson RL, Morey AF. Long-term outcomes of anastomotic urethroplasty for radiation-induced strictures. World J Urol. 2020;38(12):3055–60.

  73. Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012;61(1):112–27.

    PubMed  Google Scholar 

  74. Elshaikh MA, Ulchaker JC, Reddy CA, Angermeier KW, Klein EA, Chehade N, et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys. 2005;62(1):164–9.

    CAS  PubMed  Google Scholar 

  75. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology. 2002;60(4):650–5.

    PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge Dr. Virginia Green for editorial assistance.

Author information

Authors and Affiliations

  1. Female Pelvic Medicine and Reconstructive Surgery, Section of Urology and Renal Transplantation, Virginia Mason Franciscan Health, 1100 Ninth Avenue, C7-URO, Seattle, WA, 98101, USA

    Pansy Uberoi & Alvaro Lucioni

  2. Department of Radiology, Section of Radiation Oncology, San Antonio Military Medical Center, San Antonio, TX, USA

    Charlton A. Smith

Authors
  1. Pansy Uberoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charlton A. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alvaro Lucioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro Lucioni.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lower Urinary Tract Symptoms & Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uberoi, P., Smith, C.A. & Lucioni, A. Management of Lower Urinary Tract Symptoms after Prostate Radiation. Curr Urol Rep 22, 37 (2021). https://doi.org/10.1007/s11934-021-01048-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11934-021-01048-8

Keywords

Search

Navigation